Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Biotech Stocks: A Year in Review

Biotech Stocks: A Year in Review

Biotechs boomed in 2013, but don't expect the market to treat these companies as bargains in the new year.

Insider Trading Alert - MDVN, ACOR, MDT, UHS And CTSH Traded By Insiders

Insider Trading Alert - MDVN, ACOR, MDT, UHS And CTSH Traded By Insiders

Stocks with insider trader activity include MDVN, ACOR, MDT, UHS and CTSH

Medivation Larger Than S&P 500 Component Pitney Bowes

Medivation Larger Than S&P 500 Component Pitney Bowes

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Medivation Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Pitney Bowes Inc , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

Shire Deal Just The Start

Shire Deal Just The Start

Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.

January 2016 Options Now Available For Medivation (MDVN)

January 2016 Options Now Available For Medivation (MDVN)

Investors in Medivation Inc saw new options become available today, for the January 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

New Lifetime High Reached By Medivation (MDVN)

New Lifetime High Reached By Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

The Deal: After String of Miscues, Dendreon Likely on Block

The Deal: After String of Miscues, Dendreon Likely on Block

The one-time investor darling learned tough lessons about selling immunotherapy.

February 2014 Options Now Available For Medivation (MDVN)

February 2014 Options Now Available For Medivation (MDVN)

Investors in Medivation Inc saw new options begin trading today, for the February 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 120 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of June 2014 Options Trading For Medivation (MDVN)

First Week Of June 2014 Options Trading For Medivation (MDVN)

Investors in Medivation Inc saw new options become available this week, for the June 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Medivation, Astellas Prostate Cancer Drug Prolongs Survival

Medivation, Astellas Prostate Cancer Drug Prolongs Survival

Xtandi reduced the risk of death by 30%, more than a competing prostate cancer drug from Johnson & Johnson.

Medivation (MDVN): Heavy Pre-Market Activity

Medivation (MDVN): Heavy Pre-Market Activity

Trade-Ideas LLC identified Medivation (MDVN) as a pre-market mover with heavy volume candidate

Your Guide to Deciphering Medivation's Most Important Prostate Cancer Drug Trial

Your Guide to Deciphering Medivation's Most Important Prostate Cancer Drug Trial

Positive results from the Xtandi clinical trial could turn the prostate cancer drug into a blockbuster.

Crosscurrents and Mixed Patterns

Let us remain skeptical about this market and take another look at the buy-sell signals next Friday.

Trade-Ideas: Medivation (MDVN) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas: Medivation (MDVN) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas LLC identified Medivation (MDVN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Cramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRN

Cramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRN

Cramer said he's not betting against Netflix and has an appetite for Noodles & Co. if market weakness brings the stock price down.

Cramer's 'Mad Money' Recap: More Selling to Come

Cramer's 'Mad Money' Recap: More Selling to Come

There's nothing to like about today's down market, especially when it doesn't reflect all the bad news, Cramer said.

The Provenge Anchor Is Sinking Dendreon

The Provenge Anchor Is Sinking Dendreon

Another bad sales quarter, pulled guidance and a fleeing CFO add it up to bad news for Dendreon.

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation was a leading decliner within the drugs industry, falling $0.64 (-1.1%) to $57.23 on average volume

A Tale of Two Biotechs Under $10

A Tale of Two Biotechs Under $10

Biotech is a sector filled with speculation, risk, and potentially high reward. The fate of two companies -- one of which is now trading at less than $10 -- illustrates this.

Medivation Bulls Are Back for More

Medivation Bulls Are Back for More

Medivation already has made a big move but the bulls are looking for more.

Johnson & Johnson Gets Key Cancer Drug With Aragon Buy

Johnson & Johnson Gets Key Cancer Drug With Aragon Buy

This was a deal Johnson & Johnson had to make, as it puts pressure on its smaller rival Medivation.

Medivation Stock Falls On Unusually High Volume (MDVN)

Medivation Stock Falls On Unusually High Volume (MDVN)

Medivation (Nasdaq:MDVN) is trading at unusually high volume Monday with two million shares changing hands. It is currently at two times its average daily volume and trading down $4.79 (-9.4%).

J&J Buy of Aragon Deals a Blow to Medivation

J&J Buy of Aragon Deals a Blow to Medivation

Medivation now has a formidable competitor for prostate cancer therapy.

Ratings Changes Coming on 5/13/2013

Upgrades: AGO, AMAP, FBNC, MTEX, PTSX Downgrades: BKI, CVC, GRPN, GTIV, LINE, MDVN, SPP, SSD, VRNM Initiations: ARP, TXMD

Medivation Inc. Stock Downgraded (MDVN)

Medivation Inc. Stock Downgraded (MDVN)

Medivation (Nasdaq:MDVN) has been downgraded by TheStreet Ratings from from a hold to sell.

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation was a leading decliner within the drugs industry, falling $1.42 (-2.7%) to $50.83 on heavy volume

Medivation Breaks Below 200-Day Moving Average - Notable For MDVN

Medivation Breaks Below 200-Day Moving Average - Notable For MDVN

In trading on Wednesday, shares of Medivation Inc crossed below their 200 day moving average of $51.11, changing hands as low as $51.05 per share. Medivation Inc shares are currently trading off about 2.9% on the day.

Johnson & Johnson's Stock Looks Too Healthy

Johnson & Johnson's Stock Looks Too Healthy

JNJ's performing well, but it's hard to justify more upside from these levels given the recent rate of growth.

Medivation Inc. (MDVN): Today's Featured Health Care Mover

Medivation Inc. (MDVN): Today's Featured Health Care Mover

Medivation was a winner within the health care sector, rising 94 cents (1.8%) to $54.74 on average volume.